Description
HERZUMA (trastuzumab) is a biosimilar medication used to treat certain breast cancers that are HER2-positive. It's administered intravenously as an injection in a 420 mg dose. Manufactured by Celltrion Inc., it's a HER2/neu receptor antagonist that helps block cancer cell growth. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Trastuzumab | HTML | Access the FDA dataset for Trastuzumab — ANDA 761106 submitted by Mylan Institutional LLC | Open resource |